Skip to main content
MohsPedia/Tumor Types & Indications

Tumor Biology & Molecular Pathways in Cutaneous Oncology

Understanding the molecular pathogenesis of cutaneous malignancies is foundational for Mohs surgeons. Each major skin cancer type is driven by distinct genetic alterations: BCC by Hedgehog pathway mutations (PTCH1, SMO), SCC by TP53 and NOTCH inactivation, melanoma by MAPK pathway activation (BRAF, NRAS), MCC by Merkel cell polyomavirus T antigen oncoproteins or UV-induced mutations, and DFSP by the COL1A1-PDGFB fusion translocation. Beyond sporadic tumors, hereditary cancer syndromes such as Gorlin syndrome, xeroderma pigmentosum, Li-Fraumeni syndrome, and Muir-Torre syndrome predispose patients to multiple cutaneous malignancies requiring lifelong surveillance and frequently repeated Mohs procedures. This article reviews the key molecular pathways, actionable mutations, and genetic syndromes relevant to dermatologic surgery practice.

By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)·Published: 2026-03-13·Updated: 2026-03-13·Reviewed: 2026-03-13
tumor biologymolecular pathwayshedgehog pathwayPTCH1SMOTP53BRAFNRASMAPKMCPyVMerkel cell polyomavirusCOL1A1-PDGFBDFSPGorlin syndromexeroderma pigmentosumLi-FraumeniMuir-TorreLynch syndromegenetic syndromeshereditary cancerfield cancerizationUV mutationsNOTCHCDKN2ATERT promoterBAP1
Share

Key Takeaways

  • BCC is driven by Hedgehog pathway mutations — PTCH1 loss (most common) and SMO gain-of-function — enabling targeted therapy with vismodegib/sonidegib.
  • SCC involves sequential tumor suppressor inactivation (TP53, NOTCH1/2, CDKN2A) rather than a single dominant oncogenic pathway.
  • BRAF V600E is present in ~45% of melanomas and is the key actionable mutation for BRAF/MEK inhibitor therapy.
  • MCPyV-positive MCC is driven by viral T antigen oncoproteins that inactivate Rb and p53, while virus-negative MCC has an extremely high UV-induced mutation burden.
  • Hereditary syndromes (Gorlin, XP, Li-Fraumeni, Muir-Torre) require lifelong surveillance and alter surgical management — radiation is contraindicated in Gorlin and Li-Fraumeni syndromes.

Overview

Cutaneous malignancies arise through the stepwise accumulation of genetic alterations that disrupt normal growth regulation, DNA repair, and immune surveillance. The molecular profile of each tumor type dictates its biologic behavior, response to targeted therapy, and clinical prognosis. For the Mohs surgeon, molecular understanding informs several practical dimensions: why certain tumors exhibit extensive subclinical extension (infiltrative BCC driven by constitutive Hedgehog activation), why specific subtypes metastasize (poorly differentiated SCC with TP53/CDKN2A co-inactivation), and which patients require intensified surveillance (hereditary syndromes with germline mutations). This article organizes tumor biology by pathway rather than by tumor type, reflecting the shared molecular themes across cutaneous malignancies.

Hedgehog Signaling Pathway (BCC)

The Hedgehog (Hh) signaling pathway is the central driver of basal cell carcinoma. Under normal conditions, the transmembrane receptor Patched 1 (PTCH1) tonically inhibits the G-protein-coupled receptor Smoothened (SMO). When a Hedgehog ligand (Sonic Hedgehog, Indian Hedgehog, or Desert Hedgehog) binds PTCH1, this inhibition is released, allowing SMO to activate GLI transcription factors (GLI1, GLI2, GLI3). GLI proteins translocate to the nucleus and drive transcription of target genes including PTCH1, GLI1, CCND1, CCND2, BCL2, and FOXM1 — promoting proliferation and survival.

PTCH1 — The Gatekeeper Mutation

Loss-of-function mutations in PTCH1 are the most common genetic event in BCC, present in approximately two-thirds of sporadic tumors. PTCH1 is a classic tumor suppressor requiring biallelic inactivation (two-hit model). The first hit is typically a UV-induced point mutation; the second is loss of heterozygosity (LOH) at chromosome 9q22. When both PTCH1 alleles are inactivated, constitutive SMO signaling drives uncontrolled GLI-mediated transcription regardless of ligand binding. Germline PTCH1 mutations cause Gorlin syndrome (basal cell nevus syndrome).

SMO — Activating Mutations

Gain-of-function mutations in SMO occur in approximately 10-20% of BCCs. These mutations render SMO constitutively active, bypassing the need for PTCH1 loss. Specific SMO mutations also determine response to Hedgehog pathway inhibitors: the D473H mutation in SMO confers resistance to vismodegib, a clinically relevant resistance mechanism encountered during treatment of advanced BCC.

TP53 in BCC

TP53 mutations are the second most common genetic alteration in BCC, present in over 50% of tumors. While TP53 loss alone is insufficient to initiate BCC (unlike SCC), it cooperates with Hedgehog pathway activation to accelerate tumor growth by disabling the DNA damage checkpoint. The co-occurrence of PTCH1 loss and TP53 inactivation is associated with more aggressive tumor behavior.

Therapeutic Targets

The dependence of BCC on Hedgehog signaling created a direct therapeutic opportunity. Vismodegib and sonidegib are FDA-approved SMO inhibitors for locally advanced and metastatic BCC. Both drugs bind SMO and prevent GLI activation. Response rates in locally advanced BCC range from 43-60%, but acquired resistance develops in approximately 20% of patients, often through SMO mutations (D473H, W535L) or downstream GLI amplification.

TP53 & DNA Damage Pathways (SCC)

Cutaneous squamous cell carcinoma is driven primarily by UV-induced DNA damage and impaired DNA repair. Unlike BCC, which depends on a single dominant pathway (Hedgehog), SCC involves the sequential inactivation of multiple tumor suppressors. TP53 mutations are the earliest and most frequent genetic event, followed by NOTCH1/NOTCH2, CDKN2A, and additional oncogene activation.

TP53 — The Most Common SCC Mutation

TP53 is mutated in 50-90% of cutaneous SCCs, making it the most frequently altered gene. UV-induced TP53 mutations accumulate in chronically sun-exposed skin, creating clonal patches of p53-mutant keratinocytes that serve as the reservoir for SCC development. p53 normally functions as a transcription factor that responds to DNA damage by inducing cell cycle arrest (via p21), DNA repair, or apoptosis. Loss of p53 function eliminates this checkpoint, allowing UV-damaged cells to survive and proliferate. Notably, p53-mutant clones can be detected in histologically normal sun-exposed skin, representing subclinical actinic damage.

NOTCH Pathway Inactivation

NOTCH1 and NOTCH2 are mutated in approximately 75% of cutaneous SCCs. NOTCH receptors function as tumor suppressors in stratified squamous epithelia, promoting terminal keratinocyte differentiation and growth arrest. Loss of NOTCH signaling blocks differentiation, keeping keratinocytes in a proliferative state. NOTCH mutations are particularly frequent in immunosuppressed patients and correlate with higher-risk histology.

CDKN2A and Other Tumor Suppressors

CDKN2A encodes two tumor suppressor proteins from the same locus: p16INK4a (which inhibits CDK4/6 to enforce G1 arrest via the Rb pathway) and p14ARF (which stabilizes p53 by inhibiting MDM2). CDKN2A loss thus simultaneously disables both the Rb and p53 tumor suppressor pathways. Additional recurrently mutated genes in SCC include HRAS (activating mutations in approximately 10-15%), KNSTRN (kinastrin; ~20%, a UV-signature gene involved in kinetochore attachment), and cMYC amplification (~50% in immunosuppressed patients).

MAPK Pathway & Melanoma

Cutaneous melanoma is driven primarily by constitutive activation of the mitogen-activated protein kinase (MAPK/ERK) pathway: RAS → RAF → MEK → ERK. This signaling cascade controls cell proliferation, differentiation, and survival. Activating mutations in components of this pathway are present in over 80% of cutaneous melanomas. The specific mutation profile correlates with melanoma subtype, anatomic location, and sun exposure pattern.

BRAF V600E — The Dominant Melanoma Mutation

BRAF mutations occur in approximately 40-50% of cutaneous melanomas. The V600E missense mutation (valine to glutamic acid at codon 600) accounts for approximately 90% of BRAF mutations in melanoma. This single amino acid substitution renders BRAF constitutively active, driving continuous MEK/ERK signaling independent of upstream RAS activation. BRAF V600E is most common in melanomas arising on intermittently sun-exposed skin (trunk and extremities), in younger patients, and in superficial spreading melanomas. It is less frequent in acral, mucosal, and chronically sun-damaged melanomas.

NRAS Mutations

NRAS mutations occur in approximately 15-20% of cutaneous melanomas, predominantly at codon 61 (Q61R, Q61K, Q61L). NRAS mutations are mutually exclusive with BRAF mutations. NRAS-mutant melanomas tend to arise in chronically sun-damaged skin, present at older age, have thicker Breslow depth at diagnosis, and carry a worse prognosis compared to BRAF-mutant melanomas. MEK inhibitors (binimetinib) have shown modest activity in NRAS-mutant melanoma.

Other Melanoma Driver Mutations

C-KIT activating mutations or amplifications occur in 15-20% of acral melanomas, 20-30% of mucosal melanomas, and melanomas arising in chronically sun-damaged skin. Imatinib has demonstrated activity against C-KIT-mutant melanomas. GNAQ and GNA11 mutations (>80% prevalence) are specific to uveal melanoma and drive signaling through the PLCβ/PKC/MAPK axis. CDKN2A germline mutations are the most common cause of familial melanoma (accounting for ~40% of high-penetrance melanoma families), encoding both p16INK4a and p14ARF. NF1 loss-of-function mutations occur in approximately 10-15% of cutaneous melanomas and define a distinct molecular subtype (NF1 subtype in the TCGA classification).

TERT Promoter Mutations

Telomerase reverse transcriptase (TERT) promoter mutations are present in 70-80% of melanomas and represent a critical event in malignant transformation. These mutations (C228T and C250T) create de novo ETS transcription factor binding sites, upregulating TERT expression and enabling replicative immortality. TERT promoter mutations are a marker of transition from benign nevus (which lacks TERT mutations despite carrying BRAF V600E) to melanoma.

Merkel Cell Polyomavirus & MCC

Merkel cell carcinoma has a unique dual pathogenesis: approximately 80% of MCCs are driven by Merkel cell polyomavirus (MCPyV), while the remaining 20% are caused by UV-induced mutations. These two subtypes (virus-positive and virus-negative) represent biologically distinct diseases with different mutation profiles, immune characteristics, and prognoses.

MCPyV-Positive MCC (80%)

In virus-positive MCC, MCPyV DNA is clonally integrated into the host genome. Two viral oncoproteins drive carcinogenesis: the large T antigen (LT) and small T antigen (sT). LT contains an LxCxE motif that binds and inactivates the retinoblastoma protein (pRb), releasing E2F transcription factors to drive cell cycle progression. Critically, the integrated LT is truncated — it loses the C-terminal helicase domain required for viral replication, preventing cytopathic viral replication while preserving the oncogenic N-terminal domain. The sT antigen activates cap-dependent translation through 4E-BP1 hyperphosphorylation and stabilizes MYC and cyclin E to sustain proliferative signaling. Virus-positive MCCs characteristically have a low tumor mutation burden because they do not require the accumulation of UV-induced mutations — the viral oncoproteins substitute for these genetic hits.

MCPyV-Negative MCC (20%)

Virus-negative MCC has an extremely high tumor mutation burden — among the highest of any solid tumor — driven by UV damage. These tumors accumulate UV-signature mutations in TP53, RB1, NOTCH, and other genes. The p53/Rb pathway is disrupted through somatic mutations rather than viral oncoproteins. Despite the different mechanism, the same core pathways (Rb restriction of cell cycle, p53 DNA damage response) are disabled in both MCC subtypes, representing convergent oncogenesis.

COL1A1-PDGFB Fusion (DFSP)

Dermatofibrosarcoma protuberans is driven by a specific chromosomal translocation: t(17;22)(q22;q13), which fuses the COL1A1 gene (chromosome 17) with the PDGFB gene (chromosome 22). This translocation is present in over 90% of DFSP cases and produces a fusion protein that processes into functional PDGF-BB, establishing an autocrine growth loop through the PDGFRβ receptor. The constitutive PDGF signaling drives the characteristic infiltrative growth pattern of DFSP, with tumor cells extending along fascial planes in a tentacular fashion that makes adequate surgical margins challenging. This molecular understanding directly informed therapy: imatinib mesylate, a tyrosine kinase inhibitor that targets PDGFR, received FDA approval for unresectable, recurrent, and metastatic DFSP. Response rates with imatinib range from 50-70% in advanced DFSP.

Hereditary Cancer Syndromes

Several autosomal dominant and recessive syndromes predispose patients to cutaneous malignancies. The Mohs surgeon must recognize these syndromes because they alter management: patients require lifelong surveillance, may develop numerous primary tumors requiring repeated procedures, and carry risk for extracutaneous malignancies demanding multidisciplinary care.
SyndromeGene(s)InheritancePrimary Skin CancersKey Features
Gorlin (BCNS)PTCH1, SUFUADMultiple BCCsJaw cysts, palmoplantar pits, medulloblastoma, calcified falx
Xeroderma pigmentosumXPA-XPG, POLHARBCC, SCC, melanomaPhotosensitivity, 2000x skin cancer risk, neurodegeneration (some subtypes)
Li-FraumeniTP53ADVarious (not primary)Sarcomas, breast CA, brain tumors, adrenal CA; >90% lifetime cancer risk
Muir-TorreMSH2, MLH1ADSebaceous neoplasmsColorectal/endometrial CA; Lynch syndrome variant; MMR IHC screening
Epidermodysplasia verruciformisEVER1/TMC6, EVER2/TMC8ARHPV-driven SCCWidespread verrucous plaques; HPV types 5 and 8; sun-exposed sites
Epidermolysis bullosa (dystrophic)COL7A1AR (severe)Aggressive SCCChronic wounds → SCC; high metastatic potential; early mortality
BAP1 tumor predispositionBAP1ADAtypical Spitz tumorsUveal melanoma, mesothelioma, RCC; pink dome-shaped papules
Bazex-Dupré-ChristolACTRT1XDMultiple BCCsFollicular atrophoderma, hypotrichosis, milia
RomboUnknownADBCCsAtrophoderma vermiculata, milia, acrocyanosis
Oculocutaneous albinismTYR, OCA2, TYRP1, SLC45A2ARBCC, SCC, melanomaAbsent melanin; markedly increased photocarcinogenesis

Gorlin Syndrome (Basal Cell Nevus Syndrome)

Gorlin syndrome results from germline heterozygous mutations in PTCH1 (chromosome 9q22), with somatic loss of the remaining allele (LOH) initiating BCC development. Inheritance is autosomal dominant with high penetrance but variable expressivity. Patients develop multiple BCCs beginning in childhood or adolescence — often hundreds over a lifetime. Additional features include odontogenic keratocysts (jaw cysts), skeletal anomalies (bifid ribs, spina bifida occulta), calcification of the falx cerebri, palmoplantar pits (>85% of patients), medulloblastoma (5% risk, typically desmoplastic variant in childhood), and characteristic facies (frontal bossing, macrocephaly). Management requires lifelong dermatologic surveillance with early Mohs surgery for BCCs, combined with avoidance of ionizing radiation (which dramatically accelerates BCC development in these patients).

Xeroderma Pigmentosum

Xeroderma pigmentosum (XP) is an autosomal recessive disorder caused by mutations in nucleotide excision repair (NER) genes (XPA through XPG) or the translesion synthesis gene (XPV/POLH). NER deficiency renders patients unable to repair UV-induced DNA photoproducts (cyclobutane pyrimidine dimers and 6-4 photoproducts). XP patients develop skin cancers at 2,000 times the rate of the general population, with a median age of first skin cancer of 8 years. All three major skin cancer types (BCC, SCC, melanoma) occur with dramatically increased frequency. The mutation burden in XP tumors is extraordinarily high due to unrepaired UV damage. Management centers on rigorous photoprotection from birth and early, aggressive treatment of all premalignant and malignant lesions.

Li-Fraumeni Syndrome

Li-Fraumeni syndrome results from germline TP53 mutations (autosomal dominant). Affected individuals carry a lifetime cancer risk exceeding 90%, with sarcomas, breast cancer, brain tumors, adrenocortical carcinoma, and leukemia being the classic component tumors. Skin cancer risk, while not the defining feature, is elevated due to loss of the p53 DNA damage checkpoint. Radiation therapy should be avoided when possible, as it can induce secondary malignancies within the radiation field.

Muir-Torre Syndrome

Muir-Torre syndrome is a variant of Lynch syndrome (hereditary nonpolyposis colorectal cancer) caused by germline mutations in DNA mismatch repair (MMR) genes, most commonly MSH2 and MLH1. It is characterized by the combination of sebaceous neoplasms (sebaceous adenoma, sebaceoma, sebaceous carcinoma) and visceral malignancies (colorectal, endometrial, genitourinary). Immunohistochemistry for MMR proteins (MLH1, MSH2, MSH6, PMS2) on sebaceous neoplasms can identify patients requiring germline testing and cancer surveillance.

Other Syndromes

Additional hereditary syndromes relevant to cutaneous oncology include epidermodysplasia verruciformis (mutations in EVER1/TMC6 or EVER2/TMC8; HPV-driven SCCs, particularly types 5 and 8), epidermolysis bullosa (COL7A1 mutations in dystrophic EB; aggressive SCCs arising in chronic wounds with high metastatic potential), BAP1 tumor predisposition syndrome (germline BAP1 mutations; atypical Spitz tumors, uveal melanoma, mesothelioma, renal cell carcinoma), Bazex-Dupré-Christol syndrome (X-linked dominant; multiple BCCs, follicular atrophoderma, hypotrichosis), Rombo syndrome (autosomal dominant; BCCs, atrophoderma vermiculata, milia), and oculocutaneous albinism (OCA; mutations in TYR, OCA2, TYRP1, SLC45A2; dramatically increased risk of all UV-related skin cancers due to absent melanin photoprotection).

Cross-Cutting Molecular Themes

Several molecular themes recur across cutaneous malignancies. The TP53/Rb axis is disrupted in virtually all skin cancers — through UV-induced TP53 mutations (SCC, BCC), viral oncoprotein inactivation (MCC), or indirect disruption via CDK4/6 deregulation (melanoma). UV radiation is the dominant exogenous mutagen, generating characteristic C→T and CC→TT transitions (UV signature mutations) in BCC, SCC, and sun-exposed melanomas. The concept of field cancerization — in which the entire sun-exposed skin field accumulates oncogenic mutations — explains why patients develop multiple primary tumors and why surgical margins may harbor subclinical preneoplastic change. Immune evasion is increasingly recognized as a shared hallmark: tumors upregulate PD-L1 (SCC, MCC), lose MHC class I expression (melanoma, MCC), or recruit immunosuppressive regulatory T cells.

Implications for Mohs Surgery

Molecular biology directly informs Mohs surgical practice in several ways. First, tumor biology dictates subclinical extension patterns: infiltrative BCC (driven by constitutive Hedgehog activation) extends in thin, irregular strands that require meticulous margin assessment; DFSP (driven by PDGFB autocrine signaling) infiltrates along fascial planes requiring wider initial excision and often multiple Mohs stages. Second, immunohistochemical stains used in the Mohs lab target pathway-specific markers: cytokeratin AE1/AE3 for BCC, CK5/6 and p63 for SCC, MART-1/Melan-A and SOX10 for melanoma, and CK20 for MCC. Third, molecular understanding guides appropriate use of systemic therapy when surgery is insufficient: Hedgehog inhibitors for advanced BCC, cemiplimab for advanced SCC, BRAF/MEK inhibitors for BRAF-mutant melanoma, and imatinib for unresectable DFSP. Fourth, hereditary syndrome recognition triggers appropriate surveillance protocols and family screening.

Frequently Asked Questions

Related Articles

Basal Cell Carcinoma: Mohs Indications & TreatmentSquamous Cell Carcinoma: Mohs Indications & TreatmentMelanoma & Mohs Surgery: Indications and Slow Mohs TechniqueMerkel Cell Carcinoma: Mohs Surgery & NCCN ManagementDFSP: Mohs as Treatment of Choice (NCCN v2.2026)Systemic Therapy & Radiation for Cutaneous MalignanciesMohs Lab: Tissue Processing & Frozen Section Histology
References
  1. [1] The role of the Hedgehog signaling pathway in cancer: A comprehensive review. Bosn J Basic Med Sci. . doi:10.17305/bjbms.2018.2756
  2. [2] Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease. Cancers (Basel). . doi:10.3390/cancers13143410
  3. [3] Hedgehog signaling in basal cell carcinoma. J Dermatol Sci. . doi:10.1016/j.jdermsci.2015.02.007
  4. [4] Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin Dermatol. . doi:10.1007/s40257-016-0207-3
  5. [5] The Role of p53 in Progression of Cutaneous Squamous Cell Carcinoma. Cancers (Basel). . doi:10.3390/cancers13184507
  6. [6] Melanoma. Lancet. . doi:10.1016/S0140-6736(18)31559-9
  7. [7] Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches. Clin Exp Metastasis. . doi:10.1007/s10585-024-10291-5
  8. [8] Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review. Arch Pathol Lab Med. . doi:10.5858/arpa.2015-0475-RS
  9. [9] Merkel Cell Polyomavirus: Oncogenesis in a Stable Genome. Viruses. . doi:10.3390/v14010058
  10. [10] The Role of the Large T Antigen in the Molecular Pathogenesis of Merkel Cell Carcinoma. Genes (Basel). . doi:10.3390/genes15091127
  11. [11] Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunol Immunother. . doi:10.1007/s00262-017-2099-3
  12. [12] Gorlin Syndrome. Actas Dermosifiliogr. . doi:10.1016/j.ad.2017.07.018
  13. [13] Xeroderma pigmentosum: an updated review. Drugs Context. . doi:10.7573/dic.2022-2-5

About This Article

Author: , Fellow ACMS

Last Medical Review:

Audience: Dermatologic Surgeons

Clinic: Kaplan Clinic · DermUnbound Research Program